Climb Bio, Inc. CLYM Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $9.37M-31.8% | $13.74M+51.4% | $9.07M+38.0% | $6.58M-62.1% | $17.33M+191% | ||
| $5.84M+5.0% | $5.56M-4.5% | $5.82M+41.9% | $4.1M-27.9% | $5.69M+14.9% | ||
| $15.21M-21.2% | $19.3M+29.6% | $14.89M+39.5% | $10.68M-53.6% | $23.02M+111% | ||
| -$15.21M+21.2% | -$19.3M-29.6% | -$14.89M-39.5% | -$10.68M+53.6% | -$23.02M-111% | ||
| $1.51M-17.1% | $1.83M-10.4% | $2.04M-6.3% | $2.17M-5.0% | $2.29M-9.3% | ||
| $1.49M-16.3% | $1.78M-11.2% | $2M-0.3% | $2.01M-10.1% | $2.24M-10.3% | ||
| -$13.72M+21.7% | -$17.52M-35.9% | -$12.89M-48.7% | -$8.67M+58.3% | -$20.78M-147% | ||
| -$0.20+20.0% | -$0.25-31.6% | -$0.19-46.2% | -$0.13+58.1% | -$0.31— | ||
| -$0.20+20.0% | -$0.25-31.6% | -$0.19-46.2% | -$0.13+58.1% | -$0.31— | ||
| 68.2M+0.6% | 67.8M-0.3% | 68M+0.6% | 67.6M+0.2% | 67.5M+40.1% | ||
| 68.2M+0.6% | 67.8M-0.3% | 68M+0.6% | 67.6M+0.2% | 67.5M+40.1% | ||
| -$14M+20.2% | -$17.55M-37.8% | -$12.74M-47.5% | -$8.63M+57.9% | -$20.52M-139% | ||
| -$15.21M+21.2% | -$19.3M-29.6% | -$14.89M-39.5% | -$10.68M+53.6% | -$23.02M-111% | ||
| -$15.17M+21.2% | -$19.27M-29.6% | -$14.86M-39.7% | -$10.64M+53.8% | -$23.02M-111% | ||
| -$15.17M+21.2% | -$19.27M-29.6% | -$14.86M-39.7% | -$10.64M+53.8% | -$23.02M-111% | ||
| -$15.21M+21.2% | -$19.3M-29.6% | -$14.89M-39.5% | -$10.68M+53.6% | -$23.02M-111% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Climb Bio, Inc. profitable?
- Climb Bio, Inc. is not currently profitable: it reported a net loss of $52.8M over the trailing twelve months.
- What is Climb Bio, Inc.'s earnings per share?
- Climb Bio, Inc.'s diluted EPS over the trailing twelve months is $-0.77.
- Where does Climb Bio, Inc.'s income statement data come from?
- Every line is extracted from Climb Bio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.